Literature DB >> 16670078

The effects of saquinavir on imatinib-resistant chronic myelogenous leukemia cell lines.

Fabio Timeus, Nicoletta Crescenzio, Emanuela Ricotti, Alessandra Doria, Daniele Bertin, Giuseppe Saglio, Pier Angelo Tovo.   

Abstract

We evaluated the effect of the human immunodeficiency virus (HIV) protease inhibitor saquinavir on the imatinib-sensitive and imatinib-resistant chronic myelogenous leukemia cell lines. Saquinavir, which is also a proteasome blocker, showed dose- and time-related anti-proliferative activity, particularly on the imatinib-resistant lines and a pro-apoptotic effect. Association with imatinib caused a significant increase of activity.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16670078

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


  3 in total

1.  Anticancer effects of the nitric oxide-modified saquinavir derivative saquinavir-NO against multidrug-resistant cancer cells.

Authors:  Florian Rothweiler; Martin Michaelis; Peter Brauer; Jürgen Otte; Kristoffer Weber; Boris Fehse; Hans Wilhelm Doerr; Michael Wiese; Jörg Kreuter; Yousef Al-Abed; Ferdinando Nicoletti; Jindrich Cinatl
Journal:  Neoplasia       Date:  2010-12       Impact factor: 5.715

Review 2.  Saquinavir: From HIV to COVID-19 and Cancer Treatment.

Authors:  Mariana Pereira; Nuno Vale
Journal:  Biomolecules       Date:  2022-07-05

3.  The antiretroviral agent saquinavir enhances hTERT expression and telomerase activity in human T leukaemia cells in vitro.

Authors:  Riccardo Adamo; Alessandro Comandini; Angelo Aquino; Laura Bonmassar; Loredana Guglielmi; Enzo Bonmassar; Ornella Franzese
Journal:  J Exp Clin Cancer Res       Date:  2013-06-08
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.